Literature DB >> 28190703

Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.

Katsura Kakoki1, Yasuyoshi Miyata2, Yasushi Mochizuki1, Takahisa Iwata1, Masayuki Obatake3, Kuniko Abe4, Takeshi Nagayasu5, Hideki Sakai1.   

Abstract

Entities:  

Keywords:  Mammalian target of rapamycin inhibitor; Prognosis; Renal cell carcinoma; Sequential therapy; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2016        PMID： 28190703     DOI： 10.1016/j.clgc.2016.12.026

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  7 in total

1.  Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Authors:  Nur P Damayanti; Justin A Budka; Heba W Z Khella; Mary W Ferris; Sheng Yu Ku; Eric Kauffman; Anthony C Wood; Khunsha Ahmed; Venkata Nithinsai Chintala; Remi Adelaiye-Ogala; May Elbanna; Ashley Orillion; Sreenivasulu Chintala; Chinghai Kao; W Marston Linehan; George M Yousef; Peter C Hollenhorst; Roberto Pili
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

2.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

3.  Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.

Authors:  Zhen Wang; Ning Liu; Weidong Gan; Xiaogong Li; Gutian Zhang; Dongmei Li; Hongqian Guo
Journal:  J Int Med Res       Date:  2017-06-06       Impact factor: 1.671

4.  Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study.

Authors:  Liyuan Ge; Xiaojun Tian; Jing Ma; Guojiang Zhao; Yimeng Song; Shudong Zhang; Lulin Ma
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

5.  Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers.

Authors:  Jee Soo Park; Myung Eun Lee; Won Sik Jang; Jongchan Kim; Se Mi Park; Won Sik Ham
Journal:  Biomedicines       Date:  2022-01-29

6.  Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.

Authors:  Yuqing Wu; Saisai Chen; Minhao Zhang; Kuangzheng Liu; Jibo Jing; Kehao Pan; Lihua Zhang; Bin Xu; Xiaoming Lu; Ming Chen
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

Review 7.  Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: an adult case report and literature review.

Authors:  Yuxiong Wang; Yuantao Wang; Mingliang Feng; Xin Lian; Yongsheng Lei; Honglan Zhou
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.